Persistent URL of this record https://hdl.handle.net/1887/95617
In Collections
This item can be found in the following collections:
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
- All authors
- Henricks, L.M.; Lunenburg, C.A.T.C.; Man, F.M. de; Meulendijks, D.; Frederix, G.W.J.; Kienhuis, E.; Creemers, G.J.; Baars, A.; Dezentje, V.O.; Imholz, A.L.T.; Jeurissen, F.J.F.; Portielje, J.E.A.; Jansen, R.L.H.; Hamberg, P.; Tije, A.J. ten; Droogendijk, H.J.; Koopman, M.; Nieboer, P.; Poel, M.H.W. van de; Mandigers, C.M.P.W.; Rosing, H.; Beijnen, J.H.; Werkhoven, E. van; Kuilenburg, A.B.P. van; Schaik, R.H.N. van; Mathijssen, R.H.J.; Swen, J.J.; Gelderblom, H.; Cats, A.; Guchelaar, H.J.; Schellens, J.H.M.
- Date
- 2018-11-30
- Journal
- The Lancet Oncology
- Volume
- 19
- Issue
- 11
- Pages
- 1459 - 1467